Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | POLRMT | O00411 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.32 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25218817 | 0.88 | TMPRSS2 (0.46) | TMPRSS2POLRMT | |
| SCHEMBL30090987 | 0.87 | TMPRSS2 (0.39) | TMPRSS2 | |
| SCHEMBL30931390 | 0.86 | TMPRSS2 (0.32) | TMPRSS2SMYD2 | |
| SCHEMBL30090984 | 0.86 | TMPRSS2 (0.32) | TMPRSS2SMYD2 | |
| SCHEMBL12243216 | 0.86 | TMPRSS2 (0.32) | TMPRSS2SMYD2 | |
| SCHEMBL26124566 | 0.86 | TMPRSS2 (0.33) | TMPRSS2POLRMT | |
| SCHEMBL30091058 | 0.86 | TMPRSS2 (0.36) | TMPRSS2 | |
| SCHEMBL30091022 | 0.85 | TMPRSS2 (0.59) | TMPRSS2 | |
| SCHEMBL25909400 | 0.84 | TMPRSS2 (0.47) | TMPRSS2POLRMTTNK2PRMT5WDR77 | |
| SCHEMBL16519861 | 0.83 | TMPRSS2 (0.49) | TMPRSS2POLRMTPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118139868-A | Orally bioavailable nucleoside analogs | 维纳拓尔斯制药公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-4355755-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2024076951-A2 | ANTIVIRAL PRODRUGS AND FORMULATIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023196458-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885POLRMT 138/4885TNK2 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.